Welcome to our dedicated page for Sanuwave Health news (Ticker: SNWV), a resource for investors and traders seeking the latest updates and insights on Sanuwave Health stock.
Sanuwave Health, Inc. (SNWV) pioneers noninvasive regenerative solutions through its proprietary PACE™ technology, advancing wound care and tissue repair innovations. This dedicated news hub provides investors and medical professionals with essential updates on the company's progress in developing FDA-cleared medical devices.
Access authoritative information about SNWV's technological advancements, including clinical trial outcomes, regulatory milestones, and strategic partnerships. Our curated collection features:
• FDA clearance announcements for new medical devices
• Clinical study results demonstrating treatment efficacy
• Financial performance updates and corporate developments
• Technology licensing agreements and partnership news
Bookmark this page for reliable updates on Sanuwave Health's progress in revolutionizing noninvasive therapies for wound management, orthopedic conditions, and aesthetic procedures. Verify all investment decisions against official SEC filings and consult medical professionals for clinical guidance.
SANUWAVE Health (NASDAQ: SNWV) reported preliminary Q1 2025 revenues of $9.1-9.3 million, marking the highest Q1 revenue in company history. This represents a 57-61% increase compared to Q1 2024.
The company's UltraMIST product line showed exceptional performance with a 65% growth versus Q1 2024, contributing to approximately 99% of total revenues. The strong performance came despite a transition period involving new sales leadership and sales force restructuring.
The company manufactures all UltraMIST systems and applicators domestically, insulating it from current tariff concerns. Full Q1 2025 results are expected to be released around May 9, 2025.
SANUWAVE Health (NASDAQ: SNWV) reported record-breaking financial results for Q4 and full year 2024. Q4 revenues reached $10.3 million, up 47% year-over-year, with a gross margin of 77.9%. Full-year 2024 revenues hit $32.6 million, increasing 60% from 2023.
Key Q4 highlights include:
- 135 UltraMist® systems sold (up from 79 in Q4 2023)
- UltraMist® consumables revenue grew 59% to $5.9 million
- Operating income of $2.5 million, up 143%
- Adjusted EBITDA of $3.7 million
For 2025, SANUWAVE projects Q1 revenue of $8.4-9.0 million (45-55% YoY growth) and full-year revenue guidance of $48-50 million (47-53% growth). The company completed a 1-for-375 reverse stock split and raised $10.3 million through private placement in Q4 2024.
SANUWAVE Health (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, has scheduled a conference call to discuss its Q4 and Full Year 2024 financial results. The call will take place on March 21, 2025, at 8:30 AM ET.
Investors can access the call through toll-free (1-800-245-3047) or international (1-203-518-9765) numbers using Conference ID: SANUWAVE. Supporting materials will be available on the company's investor relations website. A replay of the call will be accessible through April 11, 2025, using the replay access ID: 11157832.
Sanuwave Health (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, has announced its approval for listing on the Nasdaq Global Market. The company's common stock will begin trading on Nasdaq on March 7, 2025, maintaining its current ticker symbol 'SNWV'.
The transition from OTCQB to Nasdaq represents a significant milestone for Sanuwave after 18 months of transition and progress. Stockholders are not required to take any action regarding the uplisting. CEO Morgan Frank expressed enthusiasm about joining one of the world's premier stock exchanges, highlighting the company's goal of transforming the wound care market and creating shareholder value.
SANUWAVE Health (OTCQB: SNWV) announced its participation in the 37th Annual Roth Conference, scheduled for March 16-18, 2025, at the Laguna Cliffs Marriott Resort & Spa in Dana Point, California. CEO Morgan Frank will be available for one-on-one meetings with investors throughout the conference.
The Annual Roth Conference is one of the nation's largest small-cap company events, featuring approximately 500 private and public companies from various growth sectors. The conference format includes company presentations, Q&A sessions, and management meetings, covering sectors such as consumer, healthcare, industrial growth, sustainability, and technology.
SANUWAVE Health specializes in non-invasive medical systems for skin, musculoskeletal tissue, and vascular structure regeneration. The company's wound care portfolio utilizes patented energy transfer technologies to support natural healing processes across wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular applications.
SANUWAVE Health reported record Q3 2024 financial results with revenues of $9.4 million, up 89% from Q3 2023. The company achieved a gross margin of 75.5% and GAAP Operating Income of $2.0 million. UltraMist® system sales increased to 124 units in Q3 2024, up from 55 in Q3 2023, while consumables revenue grew 75% to $5.4 million. Despite operational improvements, the company reported a net loss of $20.7 million, primarily due to derivative liabilities. SANUWAVE provides guidance for Q4 2024 revenue growth of 40-50% versus Q4 2023, projecting full-year 2024 revenues to exceed $32 million.
SANUWAVE Health (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, announced it will host a conference call on November 8, 2024, at 8:30 AM (ET) to discuss its Q3 2024 financial results. Participants can join via toll-free number 1-800-267-6316 or international number 1-203-518-9783 using Conference ID: SANUWAVE. Materials will be available on the company's website, and a replay will be accessible through November 29, 2024, using replay access ID: 11157276.
SANUWAVE Health announced a 1-for-375 reverse stock split effective from October 18, 2024. The common stock will trade on a split-adjusted basis under the symbol SNWV on the OTCQB, with a new CUSIP number, 80303D 305. This move will reduce the outstanding shares from approximately 1.18 billion to 3.15 million. Proportional adjustments will be made to equity awards, convertible notes, and warrants. No fractional shares will be issued; instead, fractional shares will be settled in cash. The reverse stock split will not change the total number of authorized shares or alter any stockholder's percentage interest in the company, except for adjustments due to fractional shares. Stockholders will receive transaction statements and information from the Securities Transfer regarding the exchange process.
SANUWAVE Health (OTCQB: SNWV) reported record quarterly revenues for Q2 FY2024. Key highlights include:
- Q2 2024 revenues of $7.2 million, up 53% year-over-year
- Gross margin of 73%, slightly down from 74% in Q2 2023
- GAAP Operating Income of $2.0 million
- Net income of $6.6 million, compared to a net loss of $7.3 million in Q2 2023
- Adjusted EBITDA of $1.5 million, up from $171,000 in Q2 2023
- 72 UltraMist® systems sold, up from 49 in Q2 2023
- UltraMist® consumables revenue increased by 67% to $4.7 million
The company provided guidance for Q3 2024, expecting revenue growth of 65-75% compared to Q3 2023. SANUWAVE also secured approval for a reverse stock split and 100% participation in its note and warrant exchange offer.
SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of FDA-approved wound care products, has announced a live conference call scheduled for August 13, 2024, at 8:30 AM (ET) to present their Q2 2024 financial results. Investors can access the call via toll-free (1-800-579-2543) or international (1-785-424-1789) numbers using the Conference ID: SANUWAVE. Alternatively, instant telephone access is available through a provided link.
Conference materials will be accessible on the company's website. A replay of the call will be available until September 3, 2024, using specific replay access numbers and ID. This event provides an opportunity for stakeholders to gain insights into SANUWAVE's recent financial performance and future outlook.
